Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the monoclonal antibody for the chronic inflammatory skin condition.
Related Keywords
China , Chinese , , Global Assessment , Dupilumab , Dupixent , Skin Lesions , Prurigo Nodularis , Immunoglobulin E ,
vimarsana.com © 2020. All Rights Reserved.